Compositions comprising reninangiotensin aldosterone system inhibitors and lipoic acid compounds, and the use thereof for the treatment of reninangiotensin aldosterone system related disorders

Details for Australian Patent Application No. 2009322999 (hide)

Owner Invasc Therapeutics, Inc.

Inventors Khan, Bobby V.; Parthasarathy, Sam

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2009322999

PCT Pub. Number WO2010/065069

Priority 61/118,724 01.12.08 US

Filing date 23 November 2009

Wipo publication date 10 June 2010

International Classifications

A61K 9/22 (2006.01) Medicinal preparations characterised by special physical form - Sustained or differential release type

A61K 31/195 (2006.01)

A61K 31/382 (2006.01) - having six-membered rings, e.g. thioxanthenes

A61K 31/385 (2006.01) - having two or more sulfur atoms in the same ring

A61K 31/41 (2006.01) - having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole

A61K 31/4178 (2006.01)

A61K 31/4184 (2006.01)

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

A61P 9/12 (2006.01) Drugs for disorders of the cardiovascular system

Event Publications

30 June 2011 PCT application entered the National Phase

  PCT publication WO2010/065069 Priority application(s): WO2010/065069

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009323002-Antagonists of IL-6 to raise albumin and/or lower CRP

2009322989-Perfluorocarbon gel formulations